pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

8,127 products tracked · 1,831 matching

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
Phase 3
soquelitinib
Peripheral T-Cell Lymphomas (PTCL)
$CRVSCorvus Pharmaceuticals, Inc.
1 catalysts
Phase 2
toripalimab
Loqtorzi (toripalimab-tpzi)
Esophageal Squamous Cell Carcinoma (ESCC)
Programmed cell death protein 1
$CHRSCoherus Oncology, Inc.
1 catalysts
Phase 3
tremelimumab
Imjudo (tremelimumab-actl)
Small-Cell Lung Cancer
Cytotoxic T-lymphocyte protein 4
← prev
page 6 of 62
next →
131
Pain89
Neurology1
$AZNASTRAZENECA PLC
1 catalysts
Phase 2
ubidecarenone
ubidecarenone [INN]
Metastatic Adenocarcinoma of The Pancreas
BPGbio Inc
1 catalysts
Marketed
zanubrutinib
Brukinsa (zanubrutinib)
Membranous Glomerulonephritis
Tyrosine-protein kinase BTK
$ONCBeOne Medicines Ltd.
1 catalysts
Phase 2
(atigotatug + nivolumab)
(atigotatug [INN] + nivolumab)
Small-Cell Lung Cancer
Bristol-Myers Squibb Co
0 catalysts
Phase 3
(azacitidine + cedazuridine)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Taiho Oncology Inc
0 catalysts
Marketed
(betamethasone acetate + betamethasone sodium phosphate)
Celestone Soluspan ((betamethasone acetate + betamethasone sodium phosphate))
Cerebral Edema
$OGNOrganon & Co.
0 catalysts
Preclinical
(calcipotriene + fluorouracil)
Cutaneous Squamous Cell Carcinoma (cSCC)
Phd Skin Care LLC
0 catalysts
Preclinical
(cannabidivarin + cannabigerolic acid)
Colorectal Cancer
$CNBXCNBX Pharmaceuticals Inc.
0 catalysts
Marketed
(cedazuridine + decitabine)
Inqovi ((cedazuridine + decitabine))
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Otsuka Pharmaceutical Co Ltd
0 catalysts
Phase 3
(cisplatin + vinblastine sulphate)
Dedifferentiated Liposarcoma
$INTSINTENSITY THERAPEUTICS, INC.
0 catalysts
Marketed
(cytarabine hydrochloride + daunorubicin hydrochloride)
Vyxeos ((cytarabine hydrochloride + daunorubicin hydrochloride))
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
$JAZZJazz Pharmaceuticals plc
0 catalysts
Phase 2
(docetaxel + gemcitabine) SR
(docetaxel + gemcitabine)
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
$RLMDRELMADA THERAPEUTICS, INC.
0 catalysts
Preclinical
(gemcitabine + paclitaxel)
(gemcitabine+ paclitaxel)
Pancreatic Ductal Adenocarcinoma
Duo Oncology Inc
0 catalysts
Marketed
(hyaluronidase (recombinant human) + pertuzumab + trastuzumab)
Phesgo ((hyaluronidase-zzxf (recombinant human) + pertuzumab + trastuzumab))
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast…
Genentech Inc
0 catalysts
Marketed
(hyaluronidase (recombinant, human) + rituximab)
Rituxan Hycela ((hyaluronidase (recombinant, human) + rituximab))
Chronic Lymphocytic Leukemia (CLL)
Genentech Inc
0 catalysts
Marketed
(hyaluronidase (recombinant, human) + trastuzumab)
Herceptin Hylecta ((hyaluronidase-oysk (recombinant, human) + trastuzumab))
Breast Cancer
Genentech Inc
0 catalysts
Phase 2
(nanatinostat + valganciclovir)
(nanatinostat + valganciclovir [INN])
Post-Transplant Lymphoproliferative Disorder
Viracta Therapeutics Inc
0 catalysts
Marketed
(nivolumab + relatlimab)
Opdualag ((nivolumab + relatlimab-rmbw))
Metastatic Melanoma
Bristol-Myers Squibb Co
0 catalysts
Phase 2
(prednisone + valproate sodium)
(prednisone [INN] + valproate sodium)
Diffuse Large B-Cell Lymphoma
Respiratorius AB
0 catalysts
Phase 2
(senaparib + temozolomide)
(senaparib [INN] + temozolomide)
Small-Cell Lung Cancer
IMPACT Therapeutics Inc
0 catalysts
Marketed
(tipiracil hydrochloride + trifluridine)
Lonsurf ((tipiracil hydrochloride + trifluridine))
Adenocarcinoma Of The Gastroesophageal Junction
Taiho Oncology Inc
0 catalysts
Preclinical
15d-PMJ2
Colon Cancer
Claradele Pharmaceuticals Inc
0 catalysts
Phase 2
177Lu-LNC-1011
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Yantai Lannacheng Biotechnology Co Ltd
0 catalysts
Preclinical
188-RNLBAM
Hepatocellular Carcinoma
$PSTVPLUS THERAPEUTICS, INC.
0 catalysts
Phase 1
212Pb-GRPR
Cervical Cancer
Orano Med LLC
0 catalysts
Preclinical
212Pb-LNC-1011
Prostate Cancer
Yantai Lannacheng Biotechnology Co Ltd
0 catalysts
Preclinical
3D-059
Unspecified Cancer
$SLSSELLAS Life Sciences Group, Inc.
0 catalysts
Preclinical
3D-062
Unspecified Cancer
3D Medicines Inc
0 catalysts